Orion Corporation Terminates Agreement of Ganaxolone with Marinus Pharmaceuticals in Europe
Shots:
- Orion Corporation & Marinus Pharmaceuticals have terminated the marketing and distribution agreement of ganaxolone across the EU for treating epileptic seizures in CDD patients aged 2–17yrs.
- Marinus will pay €1.5M in H1’25 on regaining European rights of ganaxolone while Orion, which paid €25M for these rights in 2021, will record a €23.5M write-down in Q4’24 following the termination
- Marinus regains the EU commercial rights and Orion halts all the launch-related preparations
Ref: Orion Corporation | Image: Orion Corporation
Related News:- Marinus Pharmaceuticals Highlights the P-III (RAISE) Study Data of Ganaxolone to Treat Refractory Status Epilepticus (RSE) at NCS 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
